NEO
Neogenomics Inc.

2,832
Loading...
Loading...
News
all
press releases
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·1mo ago
News Placeholder
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Neo Performance Materials stock surges on buyback plan
Investing.com -- Shares of Neo Performance Materials Inc (TSX:NEO) climbed 7.1% following the announcement of a Normal Course Issuer Bid (NCIB) and the commencement of trading on the OTCQX market. The Toronto-based company, specializing in advanced rare earth materials, revealed that the Toronto Stock Exchange (TSX) has accepted its notice to repurchase up to 3,297,296 of its common shares, representing approximately 10% of the public float as of May 30, 2025.
investing.com·3mo ago
News Placeholder
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences: TD Cowen...
Business Wire·7mo ago
News Placeholder
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
NeoGenomics, Inc. (Nasdaq: NEO) (the Company), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024. Fourth...
Business Wire·7mo ago
News Placeholder
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S...
Business Wire·7mo ago
News Placeholder
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year PR Newswire VANCOUVER, BC, Jan. 15, 2025 Issued on behalf...
PR Newswire·8mo ago
News Placeholder
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ:NEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial...
Business Wire·8mo ago

Latest NEO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.